Unlocking Drug Potential by Enhancing Poor Drug Solubility and Bioavailability through Hot-Melt Extrusion

Today’s drugs, not all usually soluble and easy to formulate drug actives, they might be potent drug molecules at their specific target, they can never become a successful therapy, or molecule, or product if they are not able to reach the target where they are active. So, what we are targeting in this for is making these molecules bioavailable. So, this is what we want to achieve and it can be done by the melt extrusion process. The key point of this review was to establish the relationship between a novel technology, solubility and the bioavailability profile through Hot Melt Extrusion (HME) in order to reshaping the Pharmacokinetic (PK) and Pharmacodynamic (PD) landscape for poorly soluble drugs. Tailoring the PK and PD with HME solid dosage form was shown to be affected by the physicochemical properties of the carrier matrix used. With the help of HME technology by dissolving these crystalline drug actives in a molten polymer matrix and pre-dissolved form and that makes it much more bioavailable and this enhanced the performance of such drug actives and in many cases. It is that what actively enables such molecules to at all become a drug product and a therapy. Compared to the traditional methods of developing drug products, HME is a key the gate to enhance in delivering the drug products to avoid patient compliance. A report says there are lots of developments in pharmaceutical APIs with poor solubility and improving their solubility is quite challenging. The effective formulation needs characteristics carriers and polymers that are suitable for the HME technology that has been discussed here. HME has been proven as an effective choice for the conventional ways of producing tablets, films, implants, etc. that can be administered orally, transdermal and transmucosal. This review paper adds knowledge of supercharging sluggish drugs by the use of HME and it can put the punch back in pharmaceutical industries and should use these recent developments to employ and develop cutting-edge drug delivery systems to avoid patient compliance.